AI Article Synopsis
- In 2020, significant advancements were made in blood biomarkers for Alzheimer's disease, improving diagnosis and management.
- New research focused on the treatment of status epilepticus and epilepsy, especially in women of childbearing age, alongside updated Swiss guidelines for acute stroke management and prevention.
- Progress was noted in managing NeuroMyelitis Optica Spectrum Disorder (NMO-SD), neurological presentations related to COVID-19, new treatments for migraines, and pharmacological therapies for Parkinson's disease.
Article Abstract
Significant developments were published in 2020 in the field of blood biomarkers in Alzheimer's disease. Several studies helped to define more accurately the management of status epilepticus and of epilepsy in women of childbearing age. The new Swiss guidelines for the pre-hospital management of acute stroke were issued, as are new targets for stroke prevention. Numerous advances concerning the management of NMO-SD (NeuroMyelitis Optica Spectrum Disorder) were published. Different neurological presentations linked to the COVID-19 pandemic were described (central and peripheral). Several studies confirmed the effectiveness of new migraine treatments (including anti-CGRP). New pharmacological therapies are available for Parkinson's disease.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!